Market Overview

Nanosphere Wins FDA Clearance to Market CYP2C19 Mutations Detection Test

Related NSPH
Nanosphere Offers Data from New Studies Highlighting Antibiotic Resistance Detection with Verigene Tests
Morning Market Gainers

Nanosphere, Inc. (Nasdaq: NSPH) announced today the US FDA granted 510(k) clearance permitting marketing of its CYP2C19 Nucleic Acid Test (CYP2C19 Test) on the automated sample-to-result Verigene^® System.

Posted-In: News FDA


Related Articles (NSPH)

Around the Web, We're Loving...

Get Benzinga's Newsletters